{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:05:20Z","timestamp":1748577920770,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41390-024-03474-z","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T17:02:25Z","timestamp":1724864545000},"page":"1918-1928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment"],"prefix":"10.1038","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-9322","authenticated-orcid":false,"given":"Kathryn M.","family":"Lemberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Liewehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Bornhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Lodish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"3474_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","volume":"103","author":"KI Ly","year":"2019","unstructured":"Ly, K. I. & Blakeley, J. O. The diagnosis and management of neurofibromatosis type 1. Med Clin. North Am. 103, 1035\u20131054 (2019).","journal-title":"Med Clin. North Am."},{"key":"3474_CR3","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7, e35711 (2012).","journal-title":"PLoS ONE"},{"key":"3474_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen, S. A., Yang, Q. & Friedman, J. M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am. J. Hum. Genet. 68, 1110\u20131118 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"3474_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/(SICI)1096-8628(19991203)87:4<317::AID-AJMG7>3.0.CO;2-X","volume":"87","author":"M Clementi","year":"1999","unstructured":"Clementi, M. et al. Neurofibromatosis type 1 growth charts. Am. J. Med. Genet 87, 317\u2013323 (1999).","journal-title":"Am. J. Med. Genet"},{"key":"3474_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1530\/EC-15-0102","volume":"5","author":"AS Martins","year":"2016","unstructured":"Martins, A. S. et al. Lower fasting blood glucose in neurofibromatosis type 1. Endocr. Connect 5, 28\u201333 (2016).","journal-title":"Endocr. Connect"},{"key":"3474_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1346-8138.13218","volume":"43","author":"M Koga","year":"2016","unstructured":"Koga, M., Yoshida, Y. & Imafuku, S. Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1. J. Dermatol. 43, 799\u2013803 (2016).","journal-title":"J. Dermatol."},{"key":"3474_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1530\/ERC-12-0293","volume":"19","author":"MB Lodish","year":"2012","unstructured":"Lodish, M. B. et al. Bone mineral density in children and young adults with neurofibromatosis type 1. Endocr. Relat. Cancer 19, 817\u2013825 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"3474_CR9","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3474_CR10","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3474_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss, B. D. et al. Nf106: a neurofibromatosis clinical trials consortium phase ii trial of the MEK inhibitor mirdametinib (Pd-0325901) in adolescents and adults with Nf1-related plexiform neurofibromas. J. Clin. Oncol. 39, 797\u2013806 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jid.2022.11.027","volume":"143","author":"JO Blakeley","year":"2023","unstructured":"Blakeley, J. O. et al. A call for discovery and therapeutic development for cutaneous neurofibromas. J. Invest Dermatol 143, 1351\u20131357 (2023).","journal-title":"J. Invest Dermatol"},{"key":"3474_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi, E. et al. Nf1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68, 643\u2013647 (2007).","journal-title":"Neurology"},{"key":"3474_CR14","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi, E. et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81, S33\u2013S40 (2013).","journal-title":"Neurology"},{"key":"3474_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03014467800002601","volume":"5","author":"MA Preece","year":"1978","unstructured":"Preece, M. A. & Baines, M. J. A new family of mathematical models describing the human growth curve. Ann. Hum. Biol. 5, 1\u201324 (1978).","journal-title":"Ann. Hum. Biol."},{"key":"3474_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3109\/03014460.2013.772655","volume":"40","author":"A Sayers","year":"2013","unstructured":"Sayers, A., Baines, M. & Tilling, K. A new family of mathematical models describing the human growth curve-erratum: direct calculation of peak height velocity, age at take-off and associated quantities. Ann. Hum. Biol. 40, 298\u2013299 (2013).","journal-title":"Ann. Hum. Biol."},{"key":"3474_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen, R. et al. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J. Neurooncol. 116, 307\u2013313 (2014).","journal-title":"J. Neurooncol."},{"key":"3474_CR18","doi-asserted-by":"publisher","first-page":"e30182","DOI":"10.1002\/pbc.30182","volume":"70","author":"C Rush","year":"2023","unstructured":"Rush, C., Sabus, A., Bradley, Z. K., Herbert, M. & Hemenway, M. The incidence and characterization of weight gain associated with MEK inhibitors in pediatric patients. Pediatr. Blood Cancer 70, e30182 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"3474_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2018.03.005","volume":"40","author":"K Schilbach","year":"2018","unstructured":"Schilbach, K. et al. Biomarkers of Gh action in children and adults. Growth Horm. IGF Res. 40, 1\u20138 (2018).","journal-title":"Growth Horm. IGF Res."},{"key":"3474_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1542\/peds.103.6.1257","volume":"103","author":"D Carmi","year":"1999","unstructured":"Carmi, D., Shohat, M., Metzker, A. & Dickerman, Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 103, 1257\u20131262 (1999).","journal-title":"Pediatrics"},{"key":"3474_CR21","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","volume":"23","author":"DGR Evans","year":"2017","unstructured":"Evans, D. G. R. et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin. Cancer Res 23, e46\u2013e53 (2017).","journal-title":"Clin. Cancer Res"},{"key":"3474_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24505-x","volume":"12","author":"V Botero","year":"2021","unstructured":"Botero, V. et al. Neurofibromin regulates metabolic rate via neuronal mechanisms in drosophila. Nat. Commun. 12, 4285 (2021).","journal-title":"Nat. Commun."},{"key":"3474_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trsl.2020.08.001","volume":"228","author":"R Tritz","year":"2021","unstructured":"Tritz, R. et al. Nf1 Heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. Transl. Res 228, 52\u201363 (2021).","journal-title":"Transl. Res"},{"key":"3474_CR24","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1158\/1078-0432.CCR-03-0769","volume":"10","author":"GA Mashour","year":"2004","unstructured":"Mashour, G. A. et al. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin. Cancer Res. 10, 5677\u20135683 (2004).","journal-title":"Clin. Cancer Res."},{"key":"3474_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15770-3","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo, X. et al. Midkine activation of Cd8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat. Commun. 11, 2177 (2020).","journal-title":"Nat. Commun."},{"key":"3474_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpeds.2013.10.081","volume":"164","author":"U Dagalakis","year":"2014","unstructured":"Dagalakis, U. et al. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164, 620\u2013624 (2014).","journal-title":"J. Pediatr."},{"key":"3474_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0883073812446310","volume":"28","author":"EA Soucy","year":"2013","unstructured":"Soucy, E. A. et al. Height assessments in children with neurofibromatosis Type 1. J. Child Neurol. 28, 303\u2013307 (2013).","journal-title":"J. Child Neurol."},{"key":"3474_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/jmg.37.12.933","volume":"37","author":"J Szudek","year":"2000","unstructured":"Szudek, J., Birch, P. & Friedman, J. M. Growth in North American white children with neurofibromatosis 1 (Nf1). J. Med. Genet. 37, 933\u2013938 (2000).","journal-title":"J. Med. Genet."},{"key":"3474_CR29","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/0883073818786807","volume":"33","author":"NR Zessis","year":"2018","unstructured":"Zessis, N. R., Gao, F., Vadlamudi, G., Gutmann, D. H. & Hollander, A. S. Height growth impairment in children with neurofibromatosis type 1 is characterized by decreased pubertal growth velocity in both sexes. J. Child Neurol. 33, 762\u2013766 (2018).","journal-title":"J. Child Neurol."},{"key":"3474_CR30","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1212\/WNL.0000000000012436","volume":"97","author":"C Bettegowda","year":"2021","unstructured":"Bettegowda, C. et al. Genotype-phenotype correlations in neurofibromatosis and their potential clinical use. Neurology 97, S91\u2013S98 (2021).","journal-title":"Neurology"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03474-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:31:30Z","timestamp":1748511090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03474-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1038\/s41390-024-03474-z","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"type":"print","value":"0031-3998"},{"type":"electronic","value":"1530-0447"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.M.L is an inventor on the patent (WO2022046910) for prodrugs of 6-Mercaptopurine (not relevant to the current manuscript). M.B. has a paid advisory role on the external advisory board for the Koselugo Registry through Alexion (not relevant to this manuscript). J.O.B. is a co-investigator on clinical trials supported by Alexion, SpringWorks, and Takeda (not relevant to this manuscript) and serves as Executive Director for the Neurofibromatosis Therapeutic Acceleration Program within Johns Hopkins University. B.C.W. and A.M.G. have unpaid advisory roles for AstraZeneca and SpringWorks (not relevant to this manuscript).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all participants on NCT00924196.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}]}}